Animal models of adrenocortical tumorigenesis

Endocrine Research Unit, Medizinische Klinik Campus Innenstadt, Klinikum der LMU, Ziemssenstr. 1, D-80336 Munich, Germany.
Molecular and Cellular Endocrinology (Impact Factor: 4.41). 11/2011; 351(1):78-86. DOI: 10.1016/j.mce.2011.09.045
Source: PubMed

ABSTRACT Over the past decade, research on human adrenocortical neoplasia has been dominated by gene expression profiling of tumor specimens and by analysis of genetic disorders associated with a predisposition to these tumors. Although these studies have identified key genes and associated signaling pathways that are dysregulated in adrenocortical neoplasms, the molecular events accounting for the frequent occurrence of benign tumors and low rate of malignant transformation remain unknown. Moreover, the prognosis for patients with adrenocortical carcinoma remains poor, so new medical treatments are needed. Naturally occurring and genetically engineered animal models afford a means to investigate adrenocortical tumorigenesis and to develop novel therapeutics. This comparative review highlights adrenocortical tumor models useful for either mechanistic studies or preclinical testing. Three model species - mouse, ferret, and dog - are reviewed, and their relevance to adrenocortical tumors in humans is discussed.

43 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In response to gonadectomy certain inbred mouse strains develop sex steroidogenic adrenocortical neoplasms. One of the hallmarks of neoplastic transformation is expression of GATA4, a transcription factor normally present in gonadal but not adrenal steroidogenic cells of the adult mouse. To show that GATA4 directly modulates adrenocortical tumorigenesis and is not merely a marker of gonadal-like differentiation in the neoplasms, we studied mice with germline or conditional loss-of-function mutations in the Gata4 gene. Germline Gata4 haploinsufficiency was associated with attenuated tumor growth and reduced expression of sex steroidogenic genes in the adrenal glands of ovariectomized B6D2F1 and B6AF1 mice. At 12 months after ovariectomy, wild-type B6D2F1 mice had biochemical and histological evidence of adrenocortical estrogen production, whereas Gata4(+/-) B6D2F1 mice did not. Germline Gata4 haploinsufficiency exacerbated the secondary phenotype of postovariectomy obesity in B6D2F1 mice, presumably by limiting ectopic estrogen production in the adrenal glands. Amhr2-cre-mediated deletion of floxed Gata4 (Gata4(F)) in nascent adrenocortical neoplasms of ovariectomized B6.129 mice reduced tumor growth and the expression of gonadal-like markers in a Gata4(F) dose-dependent manner. We conclude that GATA4 is a key modifier of gonadectomy-induced adrenocortical neoplasia, postovariectomy obesity, and sex steroidogenic cell differentiation.
    Endocrinology 03/2012; 153(6):2599-611. DOI:10.1210/en.2011-2135 · 4.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effectiveness of anticancer therapies relies on the ability of these substances to eliminate selectively the malignant cells with little or no toxicity to normal cells. The isolation in most human tumors of a rare subpopulation of cancer stem cells (CSCs) associated with chemo resistance lead to the "stem cell theory" (SCT). The SCT proposed that eliminating this fraction will eventually cure cancer, but experimental data supporting this classical view are controversial and are now being gradually replaced by other models. These novel models of cancer biology predict that to cure cancer only drugs or combination of drugs that eliminate all (CSCs and non-CSCs) cancer cells at once ("pankiller drugs") will be effective. The search for pankillers drugs will require tests to assess (i) the elimination of all cancer cells in in vitro systems and (ii) the ability to eradicate the tumors and prevent tumor relapse in in vivo systems. However, at present, most drugs are being tested in assays that can only provide a picture of the short-term activity of anticancer compounds. This in part explains why only a small fraction of the drugs that enter clinical trials are actually approved for clinical use. This article will provide a concise review of the systems, assays, and endpoint parameters routinely used to screen for potential anticancer drugs, and proposes, based in the current knowledge of cancer biology, a more rationale anticancer drug-screening program.
    Current Medicinal Chemistry 05/2013; 21(35). DOI:10.2174/09298673113209990009 · 3.85 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: As every experienced homeowner knows, one should never underestimate the complexity of remodeling. Three recent articles, including one in this issue of Endocrinology, highlight the remarkable complexity of tissue remodeling in the adrenal cortex.
    Endocrinology 12/2013; 154(12):4446-4449. DOI:10.1210/en.2013-1982 · 4.50 Impact Factor
Show more